Core Insights - electroCore, Inc. is participating in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York [1] - The company will host one-on-one meetings throughout the day for investors [1][2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device for chronic pain, and Quell Fibromyalgia [3] - Additionally, electroCore offers handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. reported net sales of $8.7 million for Q3 2025, a 33% increase compared to Q3 2024, and year-to-date net sales of $22.8 million, reflecting a 26% increase compared to the first nine months of 2024 [1][3][8] - The company has increased its revenue guidance for the full year 2025 to a range of $31.5 million to $32.5 million, driven by strong sales growth in the VA market for its prescription products [2][14] Financial Performance - For Q3 2025, net sales were $8.7 million, up from $6.6 million in Q3 2024, with a gross profit of $7.5 million, representing an 86% gross margin compared to 84% in the previous year [3][4][10] - Prescription device sales increased by 19% year-over-year, while health and wellness products saw a significant growth of 121% in the same period [4][8] - Total operating expenses for Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024, with selling, general, and administrative expenses rising to $9.7 million [6][7] Cash Position - As of September 30, 2025, total cash, including cash equivalents and marketable securities, was $13.2 million, an increase from $12.2 million at the end of 2024 [1][13][22] Loss and Adjusted EBITDA - The net loss for Q3 2025 was $3.4 million, or $0.40 per share, compared to a net loss of $2.5 million, or $0.31 per share, in Q3 2024 [10][20] - Adjusted EBITDA net loss for Q3 2025 was $2.0 million, slightly improved from a loss of $2.1 million in Q3 2024 [11][26] Future Outlook - The company anticipates reaching $12.0 million in quarterly revenue and achieving its first quarter of positive adjusted EBITDA in the second half of 2026 [14]